Breast cancer (BC) is a heterogeneous disease comprising several biologically different subtypes characterized by distinctive prognosis and potential therapeutic targets [
1,
2]. Although gene expression profiling technologies are capable to finely describe four main intrinsic subtypes, the logistic issues in deploying this methodology in common clinical practice has resulted in the widespread adoption of their immunohistochemistry (IHC)- defined approximation, which is still capable of predicting clinical outcome, pattern of metastatization and benefit from distinct types of therapy [
3‐
7]. Among BC subtypes, triple negative breast cancer (TNBC) represents a challenge because of its heterogeneity and the absence of a well-defined druggable target, restricting clinical decision making to chemotherapy [
8‐
10]. Different approaches have been explored to better dissect the TNBC profile in order to optimize therapeutic choices and exploit new strategies, such as genotoxic agents and interference with different DNA repair pathways [
11,
12]. Among the therapeutic options already employed in the clinical practice of several tumors including TNBC, platinum (Pt)-based compounds emerge for their ability to interfere with several cellular processes, including DNA replication and transcription [
13‐
15]. The most common Pt-salts include cisplatin (CDDP), carboplatin (CBDCA) and oxaliplatin [
16]. Of note, the activity of the single agent CBDCA was investigated through the randomized phase III trial TNT. After a median follow-up of 11 months, no significant improvements were observed in the total population in terms of overall response rate (ORR) with CBDCA versus docetaxel. However, in patients with a germline BRCA1/2 mutation, ORR was more than two-fold higher when treated with CBDCA, with a longer progression-free survival (PFS) [
17]. Regarding the molecular effects of Pt-salts, although several mechanisms of action were hypothesized and are still under investigation, the most accredited is the generation of mono-adducts, intra-strand and inter-strand (ICL) DNA cross links, able to distort the DNA backbone causing the formation of toxic single (SSB) and double (DSB) strand breaks [
16]. If not efficiently repaired, DNA damages induced by Pt-salts may cause an extensive blockage of the physiological cellular processes, including DNA replication and transcription, resulting, to an ultimate extent, in cell cycle arrest and apoptosis. The preferable DNA repair pathways acting in repairing bulky lesions induced by Pt-salts are the nucleotide excision repair (NER), the homologous recombination (HR) and the Fanconi anemia (FA) pathways [
18,
19]. Just recently, a role of base excision repair (BER) pathway has been also hypothesized [
19‐
21]. Typically, BER is active in repairing non-bulky DNA lesions induced by oxidative, alkylating or methylation stressors [
22]. Upon the recognition of the damaged base by specific glycosylases, the apurinic/apyrimidinic endonuclease 1 (APE1, also known as REF-1) cleaves the newly generated abasic site allowing the accomplishment of the DNA repair [
23]. The pivotal role of APE1 is demonstrated by its function in cellular viability and embryonic development [
24], due to its role in DNA repair activity and other recently characterized non-canonical functions. In fact, APE1 also plays an important role as redox effector on many transcriptional factors, such as NF-κB, HIF-1α, STAT-3, PAX8, AP-1 and p53 [
23‐
27], regulating important genes involved in tumor progression. Moreover, new interesting molecular functions involved in RNA metabolism were recently discovered in our laboratory [
23], including processing of damaged RNA [
28], miRNAs [
29] and abasic and oxidized ribonucleotides embedded in DNA [
30]. The different functions of APE1 are finely modulated by expression, localization, posttranslational modifications (PTMs) [
31‐
36] and by its protein-protein interactome, as well. Indeed, APE1 localizes into the nucleus with a peculiar nucleolar accumulation, which depends on active rDNA transcription [
37‐
41], but the precise significance of this subnuclear distribution is currently non-completely clear [
42]. Interestingly, a proper shuttling from nucleoli to nucleoplasm is essential for an efficient response to genotoxic damage [
43]. Up to now, it is well accepted that APE1 subcellular localization changes are associated with several cellular functions, as well as to cancer onset and progression [
28,
31,
41]. Interestingly, one of the major determinants of APE1 accumulation within nucleoli is its interaction with nucleophosmin (NPM1), which is modulated by APE1 acetylation [
41,
44]. NPM1 is a phosphoprotein, which canonically acts as a central factor in rRNA gene processing and as a chaperone in ribosome biogenesis involved in cell proliferation [
45,
46]. Depending on the cellular context, NPM1 may act both as a proto-oncogene and as a tumor suppressor and its perturbations are often involved in tumorigenesis and cancer progression [
47,
48]. The
NPM1 gene is also involved in several chromosomal translocation characterizing several tumors and involving genes such as
ALK,
RAR and
MLF1 [
49]. In addition, an aberrant overexpression of the NPM1 protein is another causing factor of several tumors including colon and ovarian cancers [
48,
50,
51]. Notably, its localization has an impact on tumorigenesis. Indeed, NPM1 prevalently localizes within the nucleoli, but it constantly shuttles between the nucleus and the cytoplasm [
45,
46,
52,
53]. We have already demonstrated that NPM1, and its localization, have an impact on BER activity. In fact, NPM1 is an important functional regulator of BER factors, specifically controlling levels and localization of BER proteins, including APE1 [
43]. Moreover, in acute myeloid leukemia (AML)- associated mutations, the mutated
NPM1 gene determines the formation of an aberrant NPM1 protein (NPM1c+) which re-localizes in the cytoplasm. This mis-localization hampers canonical functions of NPM1 [
54‐
56] and affects APE1 nuclear BER function in cancer cells, through relocalization of APE1 itself in the cytoplasm [
41]. Finally, it has been demonstrated that higher levels of APE1, often detected in several cancers, confer acquired resistance to chemotherapeutic agents [
57] and that hyperacetylation of APE1 is associated with the TNBC phenotype [
31]. For these reasons, APE1 is an emerging promising therapeutic target for cancer treatment [
58]. To this aim, research has been recently focused on the interference of APE1 functions, including the AP-endonuclease function (e.g. Compound #3) and the redox function (e.g. APX3330) [
59,
60] (Codrich et al., submitted), and on efficiently disrupting the APE1/NPM1 interaction, such as SB206553, Fiduxosin and Spiclomazine [
61]. One of our purposes was testing whether the treatment with BER inhibitors could sensitize cancer cells to genotoxic agents [
61]. Although partially investigated, the relationship between BER and Pt-salts needs to be further explored [
20,
21,
62‐
68]. Based on the above mentioned evidences, we deemed fundamental to investigate the cytotoxicity induced by the combined treatment of Pt-compounds and APE1- inhibitors, which may have synergistic therapeutic effects in the treatment of cancers such as TNBC [
69,
70].
For this reason, starting from the emerging importance of Pt-salts for the treatment of TNBC patients and, in parallel, from the continuously evolving knowledge on APE1 functions, the purpose of this study was to understand the role of APE1, and of its interactor NPM1, in TNBC cell lines treated with Pt-compounds, including CDDP and CBDCA. Specifically, by using different cancer cell lines and specific NPM1- or APE1- gene knockout cell models, we explored: i) the protective role of APE1 and NPM1 in CDDP cytotoxicity and ii) whether the APE1 and NPM1 proteins were modulated in terms of level and subcellular localization upon Pt-compounds treatment in TNBC cancer cells. Moreover, we investigated whether targeting APE1 endonuclease activity or its interaction with NPM1 may sensitize TNBC cancer cells to Pt-compounds treatment. To corroborate our in vitro data, we also considered APE1 and NPM1 levels in a real-world cohort of patients affected by TNBC and explored their potential prognostic impact for further hypothesis-generation and potential clinical utility. Finally, we analyzed the TCGA-BRCA dataset (n = 1105), focusing in particular on TNBC patients (n = 180), and identified several gene signatures whose expression levels correlated in a positive or negative way with APE1 and NPM1 expression. Notably, we examined the differences in patients that had an overall survival above/below 5 years, or that underwent disease recurrence after at least 1 year from diagnosis, highlighting the genes and the underlying molecular processes that may be involved in this different outcome.